Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS ® (raltegravir) 600 mg in the European Union

Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck  (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ISENTRESS® (raltegravir) 600 mg film-coated tablets, in combination with other anti-retroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.Language: EnglishContact: MerckMedia:Pam Eisele, 267-305-3558orCarmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news